CTL-102-GDEPT

N/A

Report date: 2024/09/10 15:05:14

Base Information

Drug NameCTL-102-GDEPT
Drug Alias NameCTL-102NTR-GDEPTCTL-102-tretazicar
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionNitric oxide synthase stimulants
TargetsNitric oxide synthase
Therapy Area/IndicationsProstatic NeoplasmsHead and Neck NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Birmingham
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInnovataUniversity Of Birmingham
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsHead and Neck NeoplasmsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A